COX inhibition (COXib),both of COX-1 and COX-2, has been associatedwith and evaluated clinically for treating various neurological andneurodegenerative diseases32−34 and psychiatric disorders, includingschizophrenia and depression.7,35−41 Despite significant research efforts into COXib, the evidence ofefficacy for COX inhibition in neurologic and psychiatric trials isstill quite mixed,42−45 and the mechanisms underlying the outcomes of COX activity and COXinhibition remain opaque. Here, PTGS2 is linked to psychiatric disorder.